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BACKGROUND: We previously reported that a faecal cyclooxygenase-2 (COX-2) mRNA assay was useful for identifying colorectal
cancer (CRC). This study sought to investigate the factors that contribute to faecal COX-2 mRNA expression in subjects with CRC.
METHODS: The study cohort comprised 78 patients with CRC and 36 control subjects. The expressions of COX-2,
b-2-microglobulin (B2M), carcinoembryonic antigen (CEA), E-cadherin (E-cad), and CD45 mRNA in faeces and COX-2 mRNA
expression in tissue were determined by quantitative real-time RT–PCR.
RESULTS: The level of faecal expression of COX-2 mRNA in CRC was significantly higher than that in controls. A significant correlation
was found between faecal COX-2 mRNA expression and faecal B2M, CEA, E-cad, or CD45 mRNAs, markers of exfoliated total cells,
colonocytes, and leukocytes, respectively. A significant correlation was found between the expression of COX-2 mRNA in faeces and
tumour surface area, COX-2 mRNA expression in primary tumour. There was no difference in faecal COX-2 mRNA expression
between proximal CRC and distal CRC.
CONCLUSION: COX-2 mRNA expression in faeces seems to originate from tumour lesion and to be affected by factors such as the
number of exfoliated cells, exfoliation of inflammatory cells, COX-2 mRNA expression in tumour, and tumour size.
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Colorectal cancer (CRC) is one of the most common causes of
cancer-related mortality worldwide. Effective screening to detect
cancer is expected to reduce the mortality rate of CRC (Mandel
et al, 1993; Hardcastle et al, 1996; Scholefield et al, 2002; Lindholm
et al, 2008). Faecal occult blood test (FOBT) is a non-invasive and
simple test reported to reduce the morbidity and mortality
associated with CRC (Mandel et al, 1993; Hardcastle et al, 1996;
Scholefield et al, 2002; Lindholm et al, 2008). However, the efficacy
of FOBT is limited because of the common occurrence of occult
bleeding from non-neoplastic sources (Osborn and Ahlquist, 2005)
and less sensitivity for proximal CRC (Morikawa et al, 2005).
Novel methods are now under development for detection of
CRC, including those based on the detection of mutated DNA,
DNA integrity (Imperiale et al, 2004; Ahlquist et al, 2008), cancer-
related methylation (Chen et al, 2005; Glockner et al, 2009), and
upregulation of cancer-related gene expression in faecal samples
(Kanaoka et al, 2004; Koga et al, 2008; Yu et al, 2008; Takai et al,
2009). We previously reported that faecal cyclooxygenase-2
(COX-2) mRNA assay is a sensitive and specific method to detect
CRC and adenoma (Kanaoka et al, 2004, 2007; Takai et al, 2009).
However, factors that contribute to faecal COX-2 mRNA expres-
sion were not well evaluated. COX-2 mRNA expression levels in
faeces may be affected by both the number of exfoliated cells that
express COX-2 mRNA and the mRNA degradation in faecal
samples. Colonocytes and inflammatory cells are reported to be
abundant in the mucocellular layer covering CRC tissue (Ahlquist
et al, 2000). Some of the colonocytes in this mucocellular layer in
CRC were reported to retain tumour-associated antigen (Ahlquist
et al, 2000), suggesting that some of them may express COX-2
mRNA. Inflammatory cells are known to express COX-2 mRNA
(Sano et al, 1995). Inflammatory cell infiltrates are commonly seen
surrounding and/or infiltrating primary tumours. Therefore, it is
possible that the degree of inflammatory cell infiltration influences
COX-2 mRNA expression in faeces. The increase in faecal COX-2
mRNA expression may be caused by the increased number of
exfoliated cells. Cell exfoliation from colonic epithelium was
known to be dramatically increased in neoplasia (Ahlquist et al,
2000; Loktionov, 2007). It is well known that COX-2 is over-
expressed in 480% of CRCs (Kawasaki et al, 2008). The difference
in COX-2 mRNA expression among colorectal tumours may affect
COX-2 mRNA expression in faeces. Tumour size can be another
factor that affects faecal COX-2 mRNA expression through the
increase in exfoliated cells and through modification of COX-2
mRNA expression in CRC (Fujita et al, 1998).
Faecal COX-2 mRNA expression may be affected by the location
of tumour, if the degradation of COX-2 mRNA in the colon is
affected by the transit time of stool in the colon.
All these factors, including the number of exfoliating cells,
inflammatory cell infiltration, the expression of COX-2 mRNA in
cancer tissue, and the size and location of the tumour, may
contribute to the expression of faecal COX-2 mRNA in CRC.
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measuring the faecal expression of b-2-microglobulin (B2M)
mRNA that is expressed at similar levels in both normal and
cancer cells (Dydensborg et al, 2006), and carcinoembryonic
antigen (CEA) and E-cadherin (E-cad) mRNAs that are expressed
in normal and CRC colonic epithelium (Benchimol et al, 1989;
Dorudi et al, 1993). CD45 mRNA, as a marker of the number of
exfoliated inflammatory cells (Charbonneau et al, 1988), and the
expression of COX-2 mRNA in tumour were also evaluated.
MATERIALS AND METHODS
Patients and samples
The institutional local genetic research ethics committee of
Hamamatsu University School of Medicine (Hamamatsu, Japan)
approved this study. All patients and subjects provided oral and
written informed consent: 78 patients with CRC who were
diagnosed colonoscopically and histologically, and 36 control
subjects with no pathological findings. Stool samples were
collected between 2 and 4 weeks after the diagnostic colonoscopy
and biopsies, and before surgery or endoscopic resection.
Collected samples for RNA isolation were initially stored at 41C
and then transferred to  801C within 24h, where they were kept
for up to 2 years. Genomic DNA was isolated from the blood of a
control subject. The median age of cancer patients and control
subjects was 68 years (range, 48–86 years) and 65 years (range,
20–87 years), respectively. Table 1 details the patient profiles. CRC
was classified according to the International Union Against Cancer
tumour-node-metastasis classification (Sobin and Wittekind,
2002). Cancer patients were classified as proximal colon cancer
(caecal, ascending, and transverse colon cancers) or distal colon
cancer (descending, sigmoid, and rectal cancers) by the location of
CRC.
In all, 60 of the 78 patients with CRC underwent curative or
palliative surgical resection of their primary lesions. Tumour
surface area was calculated by multiplying the maximum diameter
by the diameter crossing at the angle by circle ratio (Table 1).
RNA isolation
RNA was isolated from faecal samples by using a previously
published method (Kanaoka et al, 2004; Takai et al, 2009). Briefly,
3ml of Isogen (Nippon Gene, Tokyo, Japan) was added to sterile
5ml tubes each containing B0.5g of frozen faecal pellets. The
pellets were homogenised for a few minutes using a Handy
Microhomogenizer (Microtech Niti-on, Chiba, Japan). The slurries
were then poured into sterile 1.5ml tubes, and centrifuged at
12000 g for 5min at 41C. The supernatants were transferred
carefully to new sterile 1.5ml tubes. To each tube was added 0.3ml
Isogen and 0.3ml chloroform. The tubes were shaken vigorously
for 30s, and then centrifuged at 12000 g for 15min at 41C. The
aqueous phase from each tube was removed carefully, avoiding
contamination from the interface, and transferred to fresh 1.5ml
tubes. An equal volume of 70% ethanol was added, and the tubes
were vortexed vigorously for 30s. The mixed solution (0.7ml) was
added to an RNeasy minispin column (Qiagen GmbH, Hilden,
Germany), and centrifuged at 8000 g for 15s at room tempera-
ture. The remaining steps were performed according to the
manufacturer’s instructions.
RNA was extracted from biopsy materials, from DH5a
Escherichia coli cells, as well as from lactobacillus bacteria
(effective microorganism 4), using Isogen (Nippon Gene) accord-
ing to the manufacturer’s instructions. Total RNA concentrations
were determined using a NanoDrop 1000 (NanoDrop, Wilmington,
DE, USA), and the RNA samples were stored at  801C.
DNA isolation
Human genomic DNA was isolated from the blood of a control
patient using Isogen (Nippon Gene), following the manufacturer’s
instructions. Total DNA concentrations were determined using
NanoDrop 1000 (NanoDrop), and the DNA samples were stored
at  201C.
Reverse transcription
cDNA was synthesised using reverse transcriptase M-MLV
(RNaseH
 ; Takara Bio Inc., Otsu, Japan) with 1mg RNA from
faeces or tissue and 250mg random hexamers, according to the
manufacturer’s instructions. The product was then amplified using
quantitative real-time PCR.
Quantitative real-time PCR
The gene expression analysis of total isolated RNA focused on
selected genes: COX-2, B2M, CD45, CEA, and E-cad. Commercially
available TaqMan primers and probe mixtures (Applied
Biosystems, Foster City, CA, USA) were used for all reactions.
FAM was used as the reporter dye at the 50-end of probes, and
minor grove binder was used as the quencher dye at the 30-end. The
reaction mixture comprised 10ml of TaqMan Fast Universal PCR
Master Mix (Applied Biosystems), 1mlo f2 0  TaqMan primers and
probe mixture and 1ml of template cDNA or genomic DNA in a total
reaction volume of 20ml. Each PCR was performed with precycling
heat activation at 951C for 20s, followed by 60 cycles of denaturation
at 951C for 3s, and annealing and extension at 621C for 30s in an
Applied Biosystems 7500 Fast Real-Time PCR system.
A standard reference curve was established for each marker
using serial 10-fold dilutions of the recombinant plasmid DNA
containing the target sequence, which was generated using the
TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA) following
the manufacturer’s instructions. Each sample was run in triplicate
and a negative control without template was also run in each
reaction plate.
Statistical analysis
The differences in the faecal expression of target genes between
CRC patients and control subjects were analysed by the
Mann–Whitney U-test. Correlations between COX-2 mRNA
expression in faeces and that of other genes, as well as between
COX-2 and CEA mRNA expression in faeces and COX-2 and CEA
mRNA expression in cancer tissues, were determined from
Table 1 Clinical characteristics of the CRC patients and control subjects
CRC (n¼78) Control (n¼36)
Age (years), median (range) 68 (48–86) 65 (20–85)
Sex
Female:male 24:54 14:22
Tumour site
Proximal colon cancer 26
Distal colon cancer 52
Tumour surface area (cm
2), median (range) 51 (3–307)
Stage
05
I1 4
II 31
III 15
IV 13
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expression in faeces and serum CEA was also determined
from Spearman’s rank correlation. All statistical tests were two-
sided, and P values o0.05 were considered to be statistically
significant.
RESULTS
Specificity of PCR assays
In our assay, faecal RNA was isolated without separating cell
components from faeces. Therefore, RNAs isolated using our
method contain RNAs from human cells and intestinal flora. To
confirm that the mRNA evaluated in this study originated from
human cells, the specificity of PCR assays for total target gene
expressions was investigated using bacterial cDNA, human
genomic DNA, RNA isolated from faeces, and cDNA derived from
normal colon. As amplification was only observed in the cDNA
from normal colon (data not shown), all PCR assays in this study
were apparently specific for human cDNA.
COX-2, B2M, CEA, and E-cad mRNA expression in faeces
The median level of faecal COX-2 mRNA expression in CRC
patients was significantly higher than that in control subjects
(Po0.001, Table 2). The median levels of faecal B2M mRNA
(Po0.05), CEA mRNA (Po0.001), and E-cad mRNA (Po0.001,
Table 2) were also significantly higher in CRC patients than in
control subjects. For faecal samples from CRC patients, COX-2
mRNA expression was significantly correlated with B2M mRNA
(r¼0.70, Po0.001, Figure 1A), CEA mRNA (r¼0.54, Po0.001,
Figure 1B), and E-cad mRNA (r¼0.61, Po0.001, Figure 1D)
expressions, suggesting that the increased faecal expression of
COX-2 mRNA is related to the number of exfoliated cells. There
was a significant correlation between tumour surface area and
faecal expression of COX-2 mRNA, B2M mRNA, and CEA mRNA
Table 2 Marker-gene expressions in faeces
Control CRC P
COX-2 mRNA (copies) median (range) 5 (0–48) 4.4 10
2 (0–1.3 10
6) o0.001
B2M mRNA (copies) 7.0 10
3 (0–1.8 10
5) 1.2 10
4 (0–2.9 10
6) 0.024
CEA mRNA (copies) 1.0 10
2 (0–1.1 10
4) 4.4 10
2 (0–7.0 10
4) o0.001
E-cad mRNA (copies) 1.7 10
2 (0–2.3 10
3) 6.3 10
2 (0–3.7 10
5) o0.001
CD45 mRNA (copies) 0 (0–4) 25.0 (0–9.7 10
4) o0.001
P value was analysed by Mann–Whitney test; Po0.05 was considered statistically significant.
r = 0.70
P < 0.001
r = 0.54
P < 0.001
r = 0.61
P < 0.001
r = 0.89
P < 0.001
Fecal B2M mRNA expression (copies)
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Figure 1 Correlation between expressions of COX-2 mRNA and other mRNAs in faeces. (A) Correlation between faecal COX-2 and B2M mRNA
expressions in CRC. (B) Correlation between faecal COX-2 and CEA mRNA expressions in CRC. (C) Correlation between faecal COX-2 and CD45
mRNA expressions in CRC. (D) Correlation between faecal COX-2 and E-cad mRNA expressions in CRC. Spearman’s rank correlation analysis was applied
to determine the correlation.
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sin CRC patients (Table 3). These findings suggest that faecal
COX-2 mRNA expression is related to the number of exfoliated cells.
For CRC patients, there was a significant correlation between
COX-2 mRNA expression in faeces and COX-2 mRNA expression
in cancer tissues (Table 4). A significant correlation was found
between faecal expression of COX-2 mRNA and the product of
tumour surface area and tissue expression of COX-2 mRNA.
However, there was no significant correlation between CEA mRNA
expression in faeces and CEA mRNA expression in cancer tissues
(r¼ 0.12, P¼0.42) or between the product of tumour surface
area and tissue expression of CEA mRNA (r¼ 0.036, P¼0.81). A
significant correlation between faecal expression and expression
in tumour tissue suggests that faecal COX-2 mRNA expression
originated from tumour tissue. However, the absence of significant
correlation between faecal expression and expression in tumour
tissue suggests that faecal CEA mRNA expression originated from
tumour tissue and normal mucosa.
As serum CEA is a tumour marker of CRC, we evaluated the
relationship between CEA mRNA expression in faeces and serum
CEA level. There was no significant correlation between them
(r¼ 0.083, P¼0.48).
CD45 mRNA expression in faeces
Faecal expression of CD45 mRNA was significantly higher in
patients with CRC than in controls in which few expressions of
CD45 mRNA were found (Table 2). Although the absolute value of
CD45 mRNA expression is less when compared with that of COX-2
mRNA expression, the correlation between faecal CD45 and COX-2
mRNA expressions was highly significant (Figure 1C). The faecal
expression of CD45 mRNA was also correlated with tumour size
(Table 3). These findings suggest that faecal expression of COX-2
mRNA is closely related to inflammatory cell infiltration in tumour
lesions.
Comparison of marker-gene expressions in faeces
according to tumour location
As shown in Table 5, there was no significant difference in any
marker-gene expression between proximal colon cancer and distal
colon cancer (all P 40.05). These results indicate that tumour
location does not really affect COX-2 mRNA expression in faeces.
DISCUSSION
The data presented herein show the following: (1) faecal COX-2
mRNA expression is upregulated in patients with CRC, reconfirm-
ing our previous findings (Kanaoka et al, 2004, 2007; Takai et al,
2009), (2) faecal COX-2 mRNA expression is significantly
correlated with faecal B2M, CEA, and E-cad mRNA expressions
that are upregulated in CRC, (3) faecal COX-2 mRNA expression is
also significantly correlated with faecal expression of CD45 mRNA,
which is expressed only in patients with CRC, and (4) faecal COX-2
mRNA expression is significantly correlated with tumour size and
with COX-2 mRNA expression in tumour tissues, as well as with
the product of tumour size and COX-2 mRNA expression in
primary tumour.
FOBT is useful for screening CRC lesions in which bleeding
occurs easily and has been widely used as a screening test for CRC.
The introduction of FOBT in CRC screening reduced the morbidity
and mortality associated with CRC (Mandel et al, 1993; Hardcastle
et al, 1996; Scholefield et al, 2002; Lindholm et al, 2008). However,
FOBT is less sensitive for detecting proximal CRC lesions and
small lesions (Morikawa et al, 2005). We previously reported that
faecal COX-2 mRNA assay is useful for detecting CRC (Kanaoka
et al, 2004, 2007; Takai et al, 2009). However, the factors that
contribute to faecal COX-2 mRNA expression in CRC have not
been evaluated.
As exfoliated cells, which contain cancer cells, are abundant in
the mucocellular layer overlying CRC lesions and surrounding
mucosa (Ahlquist et al, 2000; Loktionov, 2007), increased faecal
COX-2 mRNA expression may be caused by the increase in these
exfoliated cells. In this study, quantitative RT–PCR for faecal
B2M mRNA expression was performed to assess the number of
exfoliated cells in faeces, and that for faecal CEA and E-cad mRNAs
expression was performed to assess the number of exfoliated
colonocytes. The faecal expressions of B2M, CEA, and E-cad
mRNAs in CRC patients were significantly higher than those in
control subjects, confirming that exfoliated cells were quantita-
tively abundant in CRC. The increase in exfoliated cells in
CRC does not directly mean an increase in the exfoliation of
COX-2 mRNA-containing cells, as the exfoliated non-malignant
colonocyte does not express COX-2 mRNA. However, the
Table 3 Correlation between tumour surface area and marker-gene
expressions in faeces
Marker Tumour surface area rP
COX-2 0.33 0.011
B2M 0.29 0.027
CEA 0.32 0.014
E-cad 0.16 0.22
CD45 0.37 0.004
Spearman’s rank correlation analysis was applied to determine the correlation;
Po0.05 was considered statistically significant.
Table 4 Correlation between COX-2 mRNA expression in faeces and
the product of COX-2 mRNA expression in cancer tissue and tumour
surface area
COX-2 mRNA
expression in faeces P
COX-2 mRNA expression in cancer tissue 0.38 0.012
COX-2 mRNA expression in cancer tissue
  tumour surface area
0.60 o0.001
Spearman’s rank correlation analysis was applied to determine the correlation;
Po0.05 was considered statistically significant.
Table 5 Marker-gene expressions in faeces according to tumour location
Proximal colon cancer (n¼26) Distal colon cancer (n¼52) P
COX-2 mRNA (copies) median (range) 5.3 10
2 (0–7.5 10
5) 3.1 10
2 (0–1.3 10
6) 0.53
B2M mRNA (copies) 1.1 10
4 (0–2.9 10
6) 1.6  10
4 (15–9.8 10
5) 0.58
CEA mRNA (copies) 5.0 10
2 (0–7.0 10
4) 3.8 10
2 (2.0–3.9 10
4) 0.68
E-cad mRNA (copies) 7.1 10
2 (0–1.1 10
5) 5.2 10
2 (0–3.7 10
5) 0.46
CD45 mRNA (copies) 20 (0–3.5 10
4) 35.0 (0–9.7 10
4) 0.69
P value was analysed by Mann–Whitney test; Po0.05 was considered statistically significant.
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ssignificant relations between faecal COX-2 mRNA and B2M, CEA,
or E-cad mRNAs suggest that increased number of exfoliated cells
may contribute to the increase in the faecal expression of COX-2
mRNA. The significant correlation between tumour size and the
faecal expression of B2M or CEA mRNAs supports the idea that the
increase in exfoliated cells in CRC originated from tumour or
surrounding tissues. The increase in faecal CD45 mRNA expres-
sion in CRC patients also support the hypothesis that exfoliated
cells are increased in CRC, as the mucocellular layer overlying CRC
lesions was reported to contain inflammatory cells (Ahlquist et al,
2000). As it is well known that inflammation promotes CRC
(Balkwill and Mantovani, 2001) and that leukocyte infiltration is
often observed within CRC tissue or surrounding tissue, the
increase in CD45 mRNA expression in faeces may reflect leukocyte
infiltration into colonic mucosa. This was supported by the fact
that faecal CD45 mRNA expression was only observed in patients
with CRC and was significantly correlated with tumour size. There
was a strong correlation between CD45 mRNA expression and
COX-2 mRNA expression, suggesting that faecal COX-2 mRNA
expression is affected by inflammatory cell infiltration in tumour
tissue. The strong correlation between faecal expressions of COX-2
and CD45 mRNAs may be caused by the involvement of
inflammation in the development of CRC. As inflammatory cells
are known to express COX-2 (Sano et al, 1995), it is also possible
that the close correlation between faecal COX-2 and CD45 mRNA
expressions was caused by the co-expression of COX-2 and CD45
mRNAs by inflammatory cells. Since ulcerative colitis or acute
inflammatory condition is susceptible to an increased number of
exfoliated epithelial and inflammatory cells, faecal COX-2 mRNA
expression is probably elevated in such inflammatory conditions.
It is very important for faecal COX-2 mRNA assay to verify
whether it could discriminate CRC from other gastrointestinal
pathologies such as inflammatory bowel conditions. We need to
clarify this issue for future studies.
It is well known that COX-2 is upregulated in not all CRC but
most CRC (Kawasaki et al, 2008). Therefore, COX-2 mRNA
expression in faeces may be affected by the degree of COX-2
mRNA expression in cancer tissues and by tumour size. In this
study, a significant relationship between faecal COX-2 mRNA
expression and COX-2 mRNA expression in cancer tissues or
tumour size was found. When we evaluated the relationship
between COX-2 mRNA expression in faeces and the product of
COX-2 mRNA expression in cancer tissue and tumour size, a
higher correlation was observed between them. This close
relationship in COX-2 mRNA expressions between cancer tissue
and faeces indicated that faecal COX-2 mRNA originated from
neoplastic lesion. These results suggested that COX-2 mRNA
expression in cancer tissue and tumour size significantly
contributed to COX-2 mRNA expression in faeces.
FOBT is reported to be less sensitive to proximal CRC than to
distal CRC (Morikawa et al, 2005). To evaluate the contribution of
tumour location to faecal COX-2 mRNA expression, we compared
the COX-2 mRNA expression in faeces between proximal CRC and
distal CRC. There was no significant difference in faecal COX-2
mRNA expression between the groups, suggesting that faecal
COX-2 mRNA assay may be useful for detecting proximal CRC and
distal CRC.
In conclusion, the results of this study suggest that faecal COX-2
mRNA expression in CRC originated from tumour or surrounding
mucosa. The amount of faecal COX-2 mRNA expression was
affected by multiple factors, including an increased number of
exfoliated cells from tumour, exfoliation of inflammatory cells,
tumour size, and COX-2 mRNA expression in tumour tissue,
however, not by tumour location.
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